This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1998 Feb;39(2):20N-22N, 36N.

Antibody pretargeted radiotherapy: a new approach and a second chance

PMID: 9476919

Free article

Antibody pretargeted radiotherapy: a new approach and a second chance

A R Fritzberg. J Nucl Med. 1998 Feb.

Free article

. 1998 Feb;39(2):20N-22N, 36N.

Author

PMID: 9476919

No abstract available

PubMed Disclaimer

Similar articles

Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Boerman OC, et al. J Nucl Med. 2003 Mar;44(3):400-11. J Nucl Med. 2003. PMID: 12621007 Review.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Clinical Trial.
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Sharkey RM, et al. J Nucl Med. 2009 Mar;50(3):444-53. doi: 10.2967/jnumed.108.058602. Epub 2009 Feb 17. J Nucl Med. 2009. PMID: 19223402
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM. Karacay H, et al. Clin Cancer Res. 2005 Nov 1;11(21):7879-85. doi: 10.1158/1078-0432.CCR-05-1246. Clin Cancer Res. 2005. PMID: 16278412
Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM. Reilly RM. J Nucl Med. 2006 Feb;47(2):196-9. J Nucl Med. 2006. PMID: 16455623 Review. No abstract available.

See all similar articles

Cited by

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
Goldenberg DM, Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J. Goldenberg DM, et al. Eur J Nucl Med Mol Imaging. 2003 May;30(5):777-80. doi: 10.1007/s00259-002-1089-6. Epub 2003 Feb 6. Eur J Nucl Med Mol Imaging. 2003. PMID: 12574971 No abstract available.
A semiempirical model of tumor pretargeting.
Liu G, Hnatowich DJ. Liu G, et al. Bioconjug Chem. 2008 Nov 19;19(11):2095-104. doi: 10.1021/bc8002748. Bioconjug Chem. 2008. PMID: 18839978 Free PMC article. Review.
Synthesis and Preliminary Biological Evaluations of Fluorescent or ¹⁴⁹Promethium Labeled Trastuzumab-Polyethylenimine.
Fitzsimmons J, Nayak T, Cutler C, Atcher R. Fitzsimmons J, et al. Biomedicines. 2015 Dec 30;4(1):1. doi: 10.3390/biomedicines4010001. Biomedicines. 2015. PMID: 28536369 Free PMC article.
Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.
Li GP, Wang YX, Huang K, Zhang H, Zhang CF. Li GP, et al. World J Gastroenterol. 2005 Apr 7;11(13):1917-21. doi: 10.3748/wjg.v11.i13.1917. World J Gastroenterol. 2005. PMID: 15800980 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire